Suppr超能文献

采用液滴数字PCR检测非小细胞肺癌中循环游离DNA中突变型EGFR L858R和外显子19浓度与EGFR-TKIs反应的相关性。

Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC.

作者信息

Zhu Yan-Juan, Zhang Hai-Bo, Liu Yi-Hong, Zhu Ya-Zhen, Chen Jun, Li Yong, Bai Jian-Ping, Liu Li-Rong, Qu Yan-Chun, Qu Xin, Chen Xian, Zheng Guang-Juan

机构信息

Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, P.R. China.

Department of Pathology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, P.R. China.

出版信息

Oncol Lett. 2017 Aug;14(2):2573-2579. doi: 10.3892/ol.2017.6425. Epub 2017 Jun 20.

Abstract

The present study aimed to determine the diagnostic concordance of plasma epidermal growth factor receptor (EGFR) mutation using droplet digital polymerase chain reaction (ddPCR) with tumor tissue samples and the predictive clinical significance of plasma EGFR mutation concentration. Plasma DNA samples from patients with non-small cell lung cancer (NSCLC) were analyzed for EGFR exon 21 codon 858 (L858R) mutation, deletion of exon 19 (ex19del) and exon 20 codon 790 (T790M) mutation using ddPCR. Firstly, the mutations in the plasma samples were compared with the matched tumor samples to determine the concordance. Secondly, image examination follow-ups were analyzed to assess the association between plasma EGFR mutation concentration and patients' response to EGFR-tyrosine kinase inhibitors (TKIs). A total of 51 patients with NSCLC were enrolled, including 48 newly diagnosed patients. Compared with tumor tissue samples, the sensitivity and specificity of ddPCR were 76.19% (16/21) and 96.55% (28/29) for mutant L858R, and 88.89% (8/9) and 100% (41/41) for ex19del, respectively. No patient exhibited the T790M mutation in the tumor tissue or plasma samples. Furthermore, 5 patients with the L858R mutation and 4 patients with ex19del in plasma and tumor tissue samples had been followed up with image examination for ≥3 months following EGFR-TKI treatment. The baseline mutant EGFR concentrations were positively correlated with a reduction in tumor burden (Spearman's r=0.7000, P=0.0358). When analyzed separately, ex19del concentrations (Spearman's r=1.0000, P<0.0001) were also positively correlated with the reduction, while mutant L858R concentrations were not (Spearman's r=0.7000, P=0.1881). In the present study, detection of plasma EGFR mutations using ddPCR exhibited sufficient concordance with tumor tissue sample results. Baseline plasma mutant EGFR and ex19del concentrations were significantly and positively correlated with response to EGFR-TKIs.

摘要

本研究旨在确定使用液滴数字聚合酶链反应(ddPCR)检测血浆表皮生长因子受体(EGFR)突变与肿瘤组织样本的诊断一致性,以及血浆EGFR突变浓度的临床预测意义。采用ddPCR分析非小细胞肺癌(NSCLC)患者的血浆DNA样本,检测EGFR第21外显子858密码子(L858R)突变、第19外显子缺失(ex19del)和第20外显子790密码子(T790M)突变。首先,将血浆样本中的突变与匹配的肿瘤样本进行比较,以确定一致性。其次,分析影像学检查随访结果,评估血浆EGFR突变浓度与患者对EGFR酪氨酸激酶抑制剂(TKIs)反应之间的关联。共纳入51例NSCLC患者,其中48例为新诊断患者。与肿瘤组织样本相比,ddPCR检测L858R突变的敏感性和特异性分别为76.19%(16/21)和96.55%(28/29),检测ex19del的敏感性和特异性分别为8,89%(8/9)和100%(41/41)。肿瘤组织或血浆样本中均未发现T790M突变患者。此外,5例血浆和肿瘤组织样本中存在L858R突变的患者以及4例存在ex19del突变的患者在接受EGFR-TKI治疗后接受了≥3个月的影像学检查随访。基线突变型EGFR浓度与肿瘤负荷减轻呈正相关(Spearman秩相关系数r=,7000,P=,0358)。单独分析时,ex19del浓度(Spearman秩相关系数r=1.0000,P<,0001)也与肿瘤负荷减轻呈正相关,而L858R突变浓度则不然(Spearman秩相关系数r=,7000,P=,1881)。在本研究中,使用ddPCR检测血浆EGFR突变与肿瘤组织样本结果具有足够的一致性。基线血浆突变型EGFR和ex19del浓度与EGFR-TKIs反应显著正相关。

相似文献

4
Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients.
Lung Cancer. 2017 Jul;109:124-127. doi: 10.1016/j.lungcan.2017.05.005. Epub 2017 May 13.
6
Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction.
Onco Targets Ther. 2015 Jun 22;8:1533-41. doi: 10.2147/OTT.S84938. eCollection 2015.

引用本文的文献

2
Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR.
PLoS One. 2022 Feb 24;17(2):e0264201. doi: 10.1371/journal.pone.0264201. eCollection 2022.
3
Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review.
Mol Diagn Ther. 2022 Jan;26(1):61-87. doi: 10.1007/s40291-021-00562-2. Epub 2021 Nov 13.
4
An electrochemiluminescence resonance energy transfer biosensor for the detection of circulating tumor DNA from blood plasma.
iScience. 2021 Aug 21;24(9):103019. doi: 10.1016/j.isci.2021.103019. eCollection 2021 Sep 24.
10
The expression level of CSDAP1 in lung cancer and its clinical significance.
Oncol Lett. 2018 Oct;16(4):4361-4366. doi: 10.3892/ol.2018.9195. Epub 2018 Jul 23.

本文引用的文献

1
Cancer treatment and survivorship statistics, 2016.
CA Cancer J Clin. 2016 Jul;66(4):271-89. doi: 10.3322/caac.21349. Epub 2016 Jun 2.
2
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
JAMA Oncol. 2015 May;1(2):149-57. doi: 10.1001/jamaoncol.2014.257.
3
Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction.
Onco Targets Ther. 2015 Jun 22;8:1533-41. doi: 10.2147/OTT.S84938. eCollection 2015.
4
Rociletinib in EGFR-mutated non-small-cell lung cancer.
N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.
6
Immunotherapy prospects in the treatment of lung cancer and mesothelioma.
Transl Lung Cancer Res. 2014 Feb;3(1):34-45. doi: 10.3978/j.issn.2218-6751.2013.11.04.
8
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.
9
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.
Clin Cancer Res. 2014 Mar 15;20(6):1698-1705. doi: 10.1158/1078-0432.CCR-13-2482. Epub 2014 Jan 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验